Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY K LAWRENCE

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1215932140
CMS profile
54548
Location
MOREHEAD CITY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$33,465.13

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY K LAWRENCE

NPI 1215932140 · CMS profile ID 54548

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

MOREHEAD CITY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215932140?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY K LAWRENCE, NPI 1215932140, CMS profile ID 54548. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215932140?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MARY K LAWRENCE, NPI 1215932140, CMS profile ID 54548. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215932140?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MARY K LAWRENCE, NPI 1215932140, CMS profile ID 54548, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1215932140?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $33,465.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–109 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $13.7702/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908579839 CMS
Novo Nordisk Inc $1,700.0002/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898755033 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.8102/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930224261 CMS
LIFESCAN, INC. $13.1802/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 919451067 CMS
Abbott Laboratories $18.5101/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910314761 CMS
Amgen Inc. $16.0001/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939321719 CMS
Corcept Therapeutics $16.0501/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948779117 CMS
Amgen Inc. $13.5401/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939321699 CMS
Abbott Laboratories $11.6101/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920428399 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,774.32 125
PY2020 $14,140.10 77
PY2021 $19,625.24 78
PY2022 $33,465.13 109
PY2023 $5,875.74 95
PY2024 $2,420.28 74
PY2025 $13,899.58 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $930,232.47 34
PY2024 Recipient $40,463.99 14
PY2024 Principal investigator $929,654.32 54
PY2023 Recipient $2,746.07 5
PY2023 Principal investigator $713,415.50 478
PY2022 Recipient $2,554.06 3
PY2022 Principal investigator $605,051.78 251
PY2021 Recipient $2,470.29 3
PY2021 Principal investigator $867,335.03 166
PY2020 Recipient $1,534.29 2
PY2020 Principal investigator $353,953.05 161
PY2019 Principal investigator $393,710.05 162

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,642.00 12/31/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533741
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187878983
Principal investigator 1 Eli Lilly and Company $1,395.66 12/17/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187883358
Principal investigator 1 ABBVIE INC. $26,932.10 11/05/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522643
Principal investigator 1 ABBVIE INC. $22,032.14 10/09/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515953
Principal investigator 1 Novo Nordisk AS $750.00 09/17/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP MOREHEAD CITY
NN9535-4801 No dispute reported 06/30/2026 1213703399
Principal investigator 1 Novo Nordisk AS $1,500.00 09/17/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP MOREHEAD CITY
NN9535-4801 No dispute reported 06/30/2026 1213756927
Principal investigator 1 Novo Nordisk AS $1,250.00 09/17/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP MOREHEAD CITY
NN9535-4801 No dispute reported 06/30/2026 1213830290
Principal investigator 1 ABBVIE INC. $18,918.25 09/04/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508466
Principal investigator 1 ABBVIE INC. $17,505.54 08/06/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502959
Principal investigator 1 Amgen Inc. $12,497.00 08/01/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246640079
Principal investigator 1 Novo Nordisk AS $2,692.37 07/21/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP MOREHEAD CITY
NN9535-4801 No dispute reported 06/30/2026 1213721307
Principal investigator 1 ABBVIE INC. $20,898.28 07/02/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202496185
Principal investigator 1 Novo Nordisk AS $1,090.80 06/25/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP MOREHEAD CITY
NN9535-4801 No dispute reported 06/30/2026 1213732364
Principal investigator 1 ABBVIE INC. $39,446.42 06/03/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489169
Principal investigator 1 ABBVIE INC. $14,473.94 05/07/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482481
Principal investigator 1 Eli Lilly and Company $297,650.60 04/28/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY No dispute reported 06/30/2026 1187878941
Principal investigator 1 ABBVIE INC. $9,445.54 04/03/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471829
Principal investigator 1 ABBVIE INC. $26,690.95 03/07/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461444
Principal investigator 1 Amgen Inc. $10,627.25 02/25/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246640081
Principal investigator 1 Eli Lilly and Company $5,096.00 02/11/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187878981
Principal investigator 1 Eli Lilly and Company $2,027.04 02/10/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883356
Principal investigator 1 ABBVIE INC. $16,230.50 02/06/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447545
Principal investigator 1 Eli Lilly and Company $590.17 01/31/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187878589
Principal investigator 1 Eli Lilly and Company $596.32 01/31/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187878591
Principal investigator 1 Novo Nordisk AS $261.63 01/31/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP MOREHEAD CITY
NN9535-4801 No dispute reported 06/30/2026 1213803398
Principal investigator 1 Novo Nordisk AS $1,925.27 01/29/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP MOREHEAD CITY
EX9536-4773 No dispute reported 06/30/2026 1213703130
Principal investigator 1 Eli Lilly and Company $46,938.00 01/28/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187875653
Principal investigator 1 Eli Lilly and Company $762.80 01/27/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187877221
Principal investigator 1 Eli Lilly and Company $65,822.00 01/21/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187875651
Principal investigator 1 Eli Lilly and Company $24,715.00 01/21/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883354
Principal investigator 1 Eli Lilly and Company $311.52 01/15/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187875649
Principal investigator 1 Eli Lilly and Company $102,164.00 01/07/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187875655
Principal investigator 1 Eli Lilly and Company $130,438.00 01/07/2025 Non-covered Recipient Entity
CARTERET MEDICAL GROUP LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187878587